RxDoctor Payments Data

Melissa Hinton

Family · St George, UTNPI 1043545536

Payments from drug & device makers

$2,836in general payments, 2019–2025

Across 154 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$666
  • Boston Scientific$396
  • Nevro Corp.$213
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$166
  • Biohaven Pharmaceuticals, Inc.$164
  • Amgen$155
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,836 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$91,070
Medicare patients
190
Services billed
1,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$19,880
JardianceEmpagliflozin13$8,414
Estradiol (Once Weekly)Estradiol13$1,362
Fentanyl11$1,244
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$1,217
Testosterone Cypionate23$983
Ondansetron Hcl46$965
Levothyroxine Sodium109$854
Losartan Potassium75$822
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$817
Omeprazole56$803
SynthroidLevothyroxine Sodium17$784
Rosuvastatin Calcium29$682
Oxycodone Hcl28$664
Albuterol Sulfate HfaAlbuterol Sulfate17$639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$101$19,88020 claims
Boehringer IngelheimJardiance$54$8,41413 claims
AbbVieSynthroid$666$78417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.

Other family in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →